Human serum albumin-3-amino-1-propanesulfonic acid conjugate inhibits amyloid-β aggregation and mitigates cognitive decline in Alzheimer's disease
Journal of Controlled Release · 2025-03 · 379 · 390-408
DOI: 10.1016/j.jconrel.2025.01.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-03. Verfasst von Divya Shastri und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea; College of Pharmacy, Keimyung University, 1095 Dalgu…. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Serum Albumin, Human, Cognitive Dysfunction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 127 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Education.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is the most commonly occurring brain disorder, characterized by the accumulation of amyloid-β (Aβ) and tau, subsequently leading to neurocognitive decline. 3-Amino-1-propanesulfonic acid (TPS) and its prodrug, currently under clinical trial III, serve as promising therapeutic agents targeting Aβ pathology by specifically preventing monomer-to-oligomer formation. Inspired by the potency of TPS prodrug, we hypothesized that conjugating TPS with human serum albumin (HSA) could enhance brain delivery and synergistically inhibit Aβ aggregation in mild to moderate AD. Thus, we prepared and extensively characterized HSA-TPS (h-TPS) conjugate using an eco-friendly coupling method. In vitro studies on Aβ aggregation kinetics and AFM imaging revealed significant prevention of Aβ aggregation. Additionally, h-TPS significantly reduced Aβ-induced neurotoxicity and H2O2-mediated reactive oxygen species (ROS) stress in SH-SY5Y cells. Moreover, h-TPS administration improved blood-brain barrier permeability and cellular uptake into neuronal cells as well as showed in vivo uptake inside the brain within 1 h. In vivo studies using an Aβ1-42-induced acute AD rat model exhibited a dose-dependent significant reduction in hippocampal Aβ levels and restoration of declined spatial learning and memory with h-TPS treatment. Overall, findings suggest that h-TPS conjugate might be a promising neuroprotective agent for preventing Aβ aggregation in mild to moderate AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea; College of Pharmacy, Keimyung University, 1095 Dalgubeol-daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
- School of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea.
- College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea. Electronic address: raj.vinit24@gmail.com.
- College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea. Electronic address: skdavid@cau.ac.kr.
Förderung
- National Research Foundation of Korea
- Ministry of Education
Zitieren
APA
Shastri, D., Raorane, C. J., Raj, V., & Lee, S. (2025). Human serum albumin-3-amino-1-propanesulfonic acid conjugate inhibits amyloid-β aggregation and mitigates cognitive decline in Alzheimer's disease. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.01.019
Vancouver
Shastri D, Raorane CJ, Raj V, Lee S. Human serum albumin-3-amino-1-propanesulfonic acid conjugate inhibits amyloid-β aggregation and mitigates cognitive decline in Alzheimer's disease. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.01.019
BibTeX
@article{Shastri2025,
author = {Shastri, Divya and Raorane, Chaitany Jayprakash and Raj, Vinit and Lee, Sangkil},
title = {Human serum albumin-3-amino-1-propanesulfonic acid conjugate inhibits amyloid-β aggregation and mitigates cognitive decline in Alzheimer's disease},
journal = {Journal of Controlled Release},
year = {2025},
doi = {10.1016/j.jconrel.2025.01.019}
}
EUVIMED